Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.

You may also be interested in...



Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)

Pfizer said that it has plans to rebound from a volatile fourth quarter of price cuts and slower than expected volume gains in emerging markets. Eli Lilly hopes to build on gains in China and boost volume growth overall in emerging markets to shore up revenues after major patents expired in key countries.

Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 1 of 2)

Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.

Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India

WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel